

Appl. No. 10/053,302
Amendment dated November 16, 2005
Reply to Final Office Action dated August 3, 2005

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma cell line with ATCC Accession No. HB 12426-~~or progeny thereof~~, antibody 3B7 produced by a hybridoma cell line with ATCC Accession No. HB 12427-~~or progeny thereof~~, and antibody 1D3 produced by the hybridoma cell line with ATCC Accession No. HB 12428-~~or progeny thereof~~.
2. (Original) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with the antibody of claim 1.
3. (Previously presented) A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding fragment of said antibody.
4. (Cancelled)
5. (Currently amended) The antibody of claim [[2]] 1, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
6. (Original) The antibody of claim 5, wherein said Type I interferon is IFN α -2/1.
7. (Currently amended) The antibody of claim [[5]] 1, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of a second Type I interferon.
8. (Currently amended) The antibody of claim 5, wherein said antibody competes for binding to IFNAR2 with antibody 1D3 produced by a hybridoma cell line with ATCC Accession No. HB 12428-~~or progeny thereof~~.

Appl. No. 10/053,302
Amendment dated November 16, 2005
Reply to Final Office Action dated August 3, 2005

9. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a monoclonal antibody.

10. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a humanized antibody.

11. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a human antibody.

12-13. (Canceled)

14. (Previously presented) A composition comprising the antibody of claims 1-3 or 9-11 and an excipient.

15. (Currently amended) An anti-IFNAR2 antibody IF3 produced by a hybridoma cell line with ATCC Accession No. HB 12426-~~or progeny thereof~~.

16. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody IF3 produced by hybridoma cell line with ATCC Accession No. HB 12426-~~or progeny thereof~~.

17. (Currently amended) An anti-IFNAR2 antibody 3B7 produced by a hybridoma cell line with Accession No. HB 12427-~~or progeny thereof~~.

18. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 3B7 produced by hybridoma cell line with ATCC Accession No. HB 12427-~~or progeny thereof~~.

Appl. No. 10/053,302
Amendment dated November 16, 2005
Reply to Final Office Action dated August 3, 2005

19. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody ID3 produced by hybridoma cell line with ATCC Accession No. HB 12428 or progeny thereof.

20. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 1D3 produced by hybridoma cell line with ATCC Accession No. HB 12428 or progeny thereof.

21. (Previously presented) The antibody of claim 7, wherein the antibody blocks the activity of IFN- α 8, IFN- α 5, IFN- α 2, and IFN- α 1.

22. (Previously presented) The antibody of claim 21, wherein the second Type I interferon is IFN- β .

23. (Previously presented) The antibody of claim 1, wherein the antibody blocks IGSF complex formation.